Quantified preferences favored higher lesion growth rate reduction (10%→50% at 18 months) as the primary driver across all ...

An offline, point-of-care algorithm on a smartphone fundus camera generated disease-specific outputs without cloud connectivity, addressing a major deployment barrier in low-resource screening ...

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could ...

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm ...

Memento Medicines, a privately held biotech developing biologic therapies for retinal disease, has launched with a $93 ...

4FRONT-1, the first 4D-150 wet AMD phase 3 trial, is being conducted in North America in treatment-naïve patients with an ...

To explore what the veligrotug approval means for patients and practice, Ophthalmology Times posed the same questions to several TED specialists, including the following: Raymond S. Douglas, MD, PhD, ...

Geographic atrophy can emerge during stable anti-VEGF regimens for bilateral wet AMD, requiring deliberate surveillance and patient counseling rather than “treat-and-forget” follow-up. Coordinating ...

Peripheral retinal lesions occurred in 54.4% of highly myopic pediatric eyes, were bilateral in 64.2%, and increased in prevalence and multiplicity with age and more negative spherical equivalent.

Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...

FDA labeling covers active and chronic TED, addressing a major evidentiary gap left by prior IGF-1R inhibition programs that primarily enrolled active disease populations. Two pivotal phase 3 trials ...